EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis

Pooja Singh iD, Vikas Kumar iD, Keun Woo Lee, Jong Chan Hong

Pharmaceuticals · 12.07.2024 · 17 (7) · 935

DOI: 10.3390/ph17070935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 12.07.2024. Verfasst von Pooja Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Life Science (BK21 Four), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Gyeongsang National University (GNU…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SHP2 belongs to a cytoplasmic non-receptor protein tyrosine phosphatase class. It plays a critical role in the development of various cancers, such as gastric cancer, leukemia, and breast cancer. Thus, SHP2 has gained the interest of researchers as a potential target for inhibiting tumor cell proliferation in SHP2-dependent cancers. This study employed pharmacophore-based virtual screening, molecular docking, molecular dynamic (MD) simulations, MM/PBSA, and principal component analysis (PCA), followed by ADME prediction. We selected three potential hits from a collective database of more than one million chemical compounds. The stability of these selected hit–protein complexes was analyzed using 500 ns MD simulations and binding free energy calculations. The identified hits Lig_1, Lig_6, and Lig_14 demonstrated binding free energies of −161.49 kJ/mol, −151.28 kJ/mol, and −107.13 kJ/mol, respectively, compared to the reference molecule (SHP099) with a ΔG of −71.48 kJ/mol. Our results showed that the identified compounds could be used as promising candidates for selective SHP2 allosteric inhibition in cancer.

Schlagwörter

Stichwörter der Autor:innen

MM-PBSAPCASHP2cancermolecular dockingmolecular dynamic simulationsreceptor-based pharmacophore modeling

Autor:innen und Institutionen

  • Division of Applied Life Science (BK21 Four), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Gyeongsang National University (GNU), 501 Jinju-daero, Jinju 52828, Republic of Korea.
  • Computational Biophysics Lab, Basque Center for Materials, Applications, and Nanostructures (BCMaterials), Buil. Martina Casiano, Pl. 3 Parque Científico UPV/EHU Barrio Sarriena, 48940 Leioa, Spain.
  • Korea Quantum Computing (KQC), 55 Centumjungang-ro, Haeundae, Busan 48058, Republic of Korea.
  • Angel i-Drug Design (AiDD), 33-3 Jinyangho-ro 44, Jinju 52650, Republic of Korea.

ORCID-Profile: Pooja Singh, Vikas Kumar

Förderung

  • National Research Foundation of Korea
  • Basic Science Research Program
  • Ministry of Education

Zitieren

APA

Singh, P., Kumar, V., Lee, K. W., & Hong, J. C. (2024). Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis. Pharmaceuticals, 17(7), 935. https://doi.org/10.3390/ph17070935

Vancouver

Singh P, Kumar V, Lee KW, Hong JC. Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis. Pharmaceuticals. 2024;17(7):935. doi:10.3390/ph17070935

BibTeX
@article{Singh2024,
  author = {Singh, Pooja and Kumar, Vikas and Lee, Keun Woo and Hong, Jong Chan},
  title = {Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {7},
  pages = {935},
  doi = {10.3390/ph17070935}
}
Kostenlos starten →